NASDAQ:GBIO Generation Bio Q2 2025 Earnings Report $0.37 -0.01 (-1.43%) As of 11:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Generation Bio EPS ResultsActual EPSN/AConsensus EPS -$0.28Beat/MissN/AOne Year Ago EPSN/AGeneration Bio Revenue ResultsActual RevenueN/AExpected Revenue$2.51 millionBeat/MissN/AYoY Revenue GrowthN/AGeneration Bio Announcement DetailsQuarterQ2 2025Date8/6/2025TimeBefore Market OpensConference Call DateWednesday, August 6, 2025Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Generation Bio Earnings HeadlinesGeneration Bio Co.: Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)July 8 at 7:14 AM | finanznachrichten.deGeneration Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)July 7 at 4:05 PM | globenewswire.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 10 at 2:00 AM | American Alternative (Ad)GBIO Generation Bio Co. - Seeking AlphaJune 26, 2025 | seekingalpha.comWe're Keeping An Eye On Generation Bio's (NASDAQ:GBIO) Cash Burn RateJune 25, 2025 | finance.yahoo.comGeneration Bio to Present at the 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comSee More Generation Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Generation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Generation Bio and other key companies, straight to your email. Email Address About Generation BioGeneration Bio (NASDAQ:GBIO) (NASDAQ: GBIO) is a clinical-stage biotechnology company focused on the development of non-viral, persistent gene therapies aimed at treating rare and prevalent diseases. Utilizing its proprietary GeneVector platform, the company engineers synthetic DNA payloads encapsulated in lipid nanoparticles to achieve safe, durable expression of therapeutic proteins. This platform is designed to overcome limitations of traditional viral vectors by offering controlled gene expression, reduced immunogenicity and scalable manufacturing processes. The company’s pipeline includes multiple preclinical and early clinical programs targeting genetic disorders of the liver, central nervous system and other organ systems. Generation Bio has announced lead programs in metabolic and hematologic diseases, with plans to expand into indications such as rare enzyme deficiencies and neurological conditions. The company leverages its integrated research, development and manufacturing capabilities to accelerate candidate selection and produce clinical-grade material in-house. Founded in 2020 and headquartered in Cambridge, Massachusetts, Generation Bio was formed through the merger of 4D Molecular Therapeutics’ non-viral gene therapy platform and Agilis Biotherapeutics’ proprietary vectors. The company maintains key research collaborations and academic partnerships across the United States and Europe, positioning it to advance global clinical development. Its facilities in Greater Boston house specialized teams in vector engineering, analytical development and process scale-up. Generation Bio’s leadership team is led by Chief Executive Officer John Evans, who brings extensive experience from previous roles at Arvinas and Pfizer. The executive team includes seasoned biopharmaceutical professionals specializing in gene therapy, regulatory affairs and operations. The company’s board of directors comprises industry veterans focused on driving innovation and strategic growth in the emerging field of non-viral gene therapy.Written by Jeffrey Neal JohnsonView Generation Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Fastenal (7/14/2025)Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.